AUS
NZ
UK
CA
USA
FRA
GER
ESP
ITA
NLD
PRT
SWE
GRC
IND
POL
BRA
ZAF
RUS
CHN
UAE
Highlights
- The benchmark of healthcare sector S&P/ASX200 Healthcare has lost nearly 11% in the last 52-weeks.
- Neuren's NDA of trofinetide for treating Rett syndrome was accepted for priority review by the FDA.
- Cryosite recently announced a dividend amount of AU$ 0.01 for the financial year ended 30 June 2022.
The S&P/ASX200 closed on Friday dropping by 95.90 points or 1.40% to 6,747.00. The index ended this week with a loss of 0.74%. The benchmark of healthcare sector S&P/ASX200 Healthcare also ended this week with a loss of 3.47% but the index is up by 5.45% this quarter. In the last 52-weeks the index has lost nearly 11%.
With this backdrop, we will discuss some of the healthcare stocks from ASX that have provided over 90% returns in the last 52 weeks (As of 16 Sep 2022).
Neuren Pharmaceuticals Ltd (ASX:NEU)
Neuren Pharmaceuticals is engaged in developing drugs for neurological disorders. Shares of the Australian biopharmaceutical company are up by around 223.0% in the past 52 weeks.
Anteris Technologies Ltd (ASX:AVR)
Anteris Technologies, an ASX-listed structural heart company, has gained about 199.0% in the past 52-weeks. In the half year ended 30 June 2022, Anteris reported a 22% decline in its revenue from ordinary activities. Similarly, the company incurred a loss of about AU$22 million. The company's major activities during the period are as follows:
- Continued research and development of regenerative medicine
- Production and sale of its proprietary ADAPT® regenerative tissue products on a global basis
Neurotech International Ltd (ASX:NTI)
In the financial year ended 30 June 2022, Neurotech reported an 81% decline in revenue from ordinary activities with a loss of AU$3.3 million.
However, shares of the medical device and solutions company are up by around 111.4% in the last 52-weeks.
During the reporting period, Neurotech was focused on delivering solutions for treating conditions that improve quality of life. It involves clinical studies to assess the neuro-protective, anti-inflammatory and neuromodulatory activities of the company's proprietary NTI/Dolce cannabis strains.
Cryosite Ltd (ASX:CTE)
Cryosite Limited offers outsourced clinical trials logistic services. The company's stock value has been up by about 95.1% in the last 52-weeks.
Cryosite recently announced a dividend amount of AU$ 0.01 for the financial year ended 30 June 2022. The company's revenue from ordinary activities increased by 17% during the reporting period. It generated a net profit of AU$1.36million, up by 109%. Its earnings per share were 2.79 cents. Similarly, the company's cash from operations was AU$2.5 million compared to AU$0.5 million in FY21.
